Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imidafenacin - Kyorin Pharmaceutical/Ono Pharmaceutical

Next Previous
Drug Profile

Imidafenacin - Kyorin Pharmaceutical/Ono Pharmaceutical

Alternative Names: KRP 197; KRP-197OD; ONO 8025; ONO-8025OD; Staybla; Staybla OD Tablets; Uritos; Uritos OD Tablets

Latest Information Update: 25 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Ajanta Pharma; Chong Kun Dang; Eisai Co Ltd; Kyorin Pharmaceutical; Ono Pharmaceutical
  • Class Imidazoles; Small molecules; Urologics
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder; Pollakisuria; Urinary incontinence
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 25 Jul 2025 Launched for Overactive bladder in Myanmar, Laos, Vietnam, Cambodia, Indonesia, Philippines (PO)
  • 12 Apr 2021 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Japan (PO)
  • 01 Aug 2018 Imidafenacin licensed to Faes Farma in Latin America

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top